Ionis Pharmaceuticals announced favorable Phase 3 results for oleazarsen, its antisense oligonucleotide drug that significantly reduced triglyceride levels by up to 72% and decreased acute pancreatitis events by 85% in patients with severe hypertriglyceridemia. These outcomes position oleazarsen for expanded regulatory labeling and broader commercial opportunity. The trials, Core and Core2, underscored favorable safety and tolerability profiles supporting long-term use.